Elevance Health's Q3 earnings report led to a 14% stock price drop due to increased benefit expense ratio and declining EPS. The health insurance industry faces challenges, particularly in Medicare Advantage and Medicaid, affecting profitability and causing industry-wide share price declines. Elevance's management expects revenue growth in 2025 but acknowledges ongoing profitability issues, suggesting a cautious outlook for the near term.
ELV's third-quarter earnings are hurt by declining membership in Medicaid and Medicare, partially offset by improved product revenues.
Elevance Health Inc. ELV reported on Thursday third-quarter revenues of $44.7 billion, up 5.3% year-over-year, beating the consensus of $43.33 billion.
CNBC's Bertha Coombs reports on Elevance Health's quarterly earnings results.
Elevance Health (ELV) shares cratered Thursday after the insurer posted a lower-than-expected profit and slashed its outlook on falling Medicaid enrollments.
Although the revenue and EPS for Elevance Health (ELV) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
On Thursday, Elevance Health Inc. ELV reported third-quarter revenues of $44.7 billion, up 5.3% year-over-year, beating the consensus of $43.33 billion.
Elevance Health (ELV) came out with quarterly earnings of $8.37 per share, missing the Zacks Consensus Estimate of $9.70 per share. This compares to earnings of $8.99 per share a year ago.
“We remain confident in the long-term earnings potential of our diverse businesses as we navigate a dynamic operating environment and unprecedented challenges in the Medicaid business,” Chief Executive Gail K. Boudreaux said in prepared remarks.
Elevance Health cut its full-year profit forecast on Thursday, as it expects to pay out more in claims due to robust demand for medical care from members in its government-backed plans, sending its shares down 6% in premarket trading.
Elevance Health (ELV) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
ELV's third-quarter results are likely to reflect growing operating income from the Carelon business.